Moderna Forecast -8.2%: Plunge as $39 Target Alarms Bulls
Can Moderna’s pipeline story outweigh a brutal valuation reset, or is the latest sell-off warning investors not to chase the rally? Maik Kemper Editor in Chief Because it…
BioNTech Oncology Faces $1B Buyback Warning Before ASCO
Can BioNTech Oncology turn its huge cash pile into a real cancer breakthrough before investors lose patience? Maik Kemper Editor in Chief Our presentations at this year’s ASCO…
Moderna Hantavirus +12% Rally: Can The Surge Last?
Is the Moderna Hantavirus buzz really powering MRNA’s double-digit rally, or are traders simply chasing the next outbreak story? Maik Kemper Editor in Chief Conclusion In the end,…
Amgen Earnings -5.3% Plunge: Guidance Shock Despite Upgrade
Are the latest Amgen Earnings a buying opportunity after the stock’s sudden plunge, or a warning sign that growth is stalling? Maik Kemper Editor in Chief The quarter…
Evotec Earnings +8% Surge: Are Smaller Losses Enough?
Are the latest Evotec Earnings and an 8% share price surge the start of a real turnaround or just another relief rally? Maik Kemper Editor in Chief We…
BioNTech Leadership Change: -17.9% Crash After Billion-Euro Loss
Can BioNTech’s surprise leadership change and deepening losses turn a Covid-era star into a long-term oncology value play or a value trap? How did markets react to BioNTech…